One Platform. Multiple Markets.
Breakthrough Impact.
DNA mutations tell you what previously changed for patients.
Our tests reveal what's happening now — reading the layered epigenetic signatures conventional tests cannot see.
Detect earlier. Monitor smarter. Power richer trials.
A New Layer of Cancer Detection
Reading the biological signals in blood that conventional liquid biopsies miss — from less than 1 mL of plasma.
Today's Blind Spot
Most liquid biopsies look for one thing: genetic mutations shed by tumors into the bloodstream. But in early-stage cancer, those mutations are often too rare to find — like searching for a handful of typos in a library. By the time the signal is strong enough to detect, the disease has often progressed.
At Stage 0 and Stage I — when treatment outcomes are best — mutation-based tests frequently come up empty.
The Signal Others Miss
Cancer doesn't just rewrite the genetic code — it changes how that code is packaged and controlled. We read these regulatory changes one molecule at a time, capturing a far richer picture of the disease. Crucially, this signal remains visible even when mutation-based tests go silent.
Peer-reviewed evidence shows our approach delivers accurate cancer detection — independent of DNA sequencing.
(Fedyuk et al., Nature Biotechnology, 2022)
Explore the Story
Dive deeper into the science, the markets, and the team building the future of cancer diagnostics.
Applications
From early breast cancer screening to recurrence monitoring and smarter clinical trials.
Platform
The science: how we read cancer's hidden signals one molecule at a time.
Market Opportunity
A multi-billion-dollar opportunity across liquid biopsy, screening, and companion diagnostics.
Team
Proven operators in diagnostics, single-molecule science, and biotech commercialization.
Invest in the next generation of cancer diagnostics.
We're raising our Seed Round to accelerate clinical validation, regulatory milestones, and BioPharma partnerships — and we're inviting a select group of mission-aligned investors to join us at the ground floor.
For accredited investors and institutional partners. All inquiries treated confidentially.